PRO32 Extended Half-Life (EHL) Recombinant Factor VIII (RFVIII) for the Treatment of Hemophilia a in Italy: Cost of Treatment Comparison
Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.1017
https://www.valueinhealthjournal.com/article/S1098-3015(21)01234-1/fulltext
Title :
PRO32 Extended Half-Life (EHL) Recombinant Factor VIII (RFVIII) for the Treatment of Hemophilia a in Italy: Cost of Treatment Comparison
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)01234-1&doi=10.1016/j.jval.2021.04.1017
First page :
Section Title :
Open access? :
No
Section Order :
10515